Allos Therapeutics (ALTH) Reports Inline Q3 Loss of $0.21
More News related to ALTH
- Allos Therapeutics Announces New Data on FOLOTYN(TM) to be Presented at the American Society of Hematology Meeting
- Allos Therapeutics to Present at Upcoming Conferences in November
- NCCN Receives Research Grant to Evaluate Pralatrexate in Solid Tumors and Hematologic Malignancies
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Allos Therapeutics (ALTH) Reports Inline Q3 Loss of $0.21
More News related to Earnings
- Massive Deficits Plague the U.S.
- The "Buy Stuff" Bell Is Ringing, Are You Listening?
- AnnTaylor (ANN) Shares Rallying as Analyst Sees Attractive Entry Point, Upgrades to Overweight
- Best of the Web 11/23: Suicides On the Rise, U.S. Debt Service Could Top $700B, Really? An Insider Trading Beauty Queen
- Bank of America's Ken Lewis Is Offering to Stay
Allos Therapeutics, Inc. (NASDAQ: ALTH) reports Q3 loss of $0.21, inline with the analyst estimate of ($0.21).
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
